Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Checkpoint inhibitors and thrombosis: what’s up?

Jan Beyer-Westendorf

Blood (2021) 137 (12): 1569–1570.

https://doi.org/10.1182/blood.2020009480

Published: 2021

Journal Articles

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Florian Moik, Wei-Shin Evelyn Chan, Sarah Wiedemann, Christoph Hoeller, Felix Tuchmann, Marie-Bernadette Aretin, Thorsten Fuereder, Sabine Zöchbauer-Müller, Matthias Preusser, Ingrid Pabinger, Cihan Ay

Blood (2021) 137 (12): 1669–1678.

https://doi.org/10.1182/blood.2020007878

Published: 2021

Includes: Supplemental data

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Anastasiya V Beynarovich, MD, Kirill Lepik, Nataliia Mikhailova, Elena Kondakova, Yuri Zalaylov, Evgeniya Borzenkova, Elena Babenko, Elena I Darskaya, MD PhD, Ivan S Moiseev, MD PhD, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 1561.

https://doi.org/10.1182/blood-2019-129076

Published: 2019

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

Journal Articles

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Chloe B. Steen, MSc, Bogdan A. Luca, PhD, Mohammad Shahrokh Esfahani, Barzin Y. Nabet, PhD, Brian Sworder, MD PhD, Farshad Farshidfar, MD PhD, Kiarash Shamardani, BA, David M. Kurtz, MD PhD, Chih Long Liu, PhD, Ranjana H Advani, MD, Yasodha Natkunam, MD PhD, June Helen Myklebust, PhD, Maximilian Diehn, MD PhD, Andrew Gentles, PhD, Aaron M Newman, PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 655.

https://doi.org/10.1182/blood-2019-129461

Published: 2019

Journal Articles

Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease

Hideaki Fujiwara, Anna V Mathew, Ilya Kovalenko, Pal Anupama, Dan Peltier, Stephanie Kim, Austin Taylor, BA, Katherine Oravecz-Wilson, Yaping Sun, Costas Lyssiotis, Alnawaz Rehemtulla, Subramanian Pennarthur, Pavan Reddy

Blood (2019) 134 (Supplement_1): 584.

https://doi.org/10.1182/blood-2019-126775

Published: 2019

Journal Articles

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Jean-Pierre Delord, MD, Nuria Kotecki, MD, Aurelien Marabelle, MD PhD, Armelle Vinceneux, MD, Iphigenie Korakis, MD, Christiane Jungels, MD, Stéphane Champiat, MD, Richard D. Huhn, MD, Nicolas Poirier, PhD, Dominique Costantini, MD, Bérangère Vasseur, MD, Philippe A. Cassier, MD

Blood (2019) 134 (Supplement_1): 1040.

https://doi.org/10.1182/blood-2019-124876

Published: 2019

Journal Articles

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Partow Kebriaei, MD, Pinaki P Banerjee, PhD, Christina Ganesh, BSN, RN, Mecit Kaplan, MS, Vandana Nandivada, BS, MS, Ana Karen Nunez Cortes, MD, Amin M. Alousi, MD, David Marin, MD, Elizabeth J. Shpall, MD, Rohtesh Mehta, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Katayoun Rezvani, MD PhD

Blood (2019) 134 (Supplement_1): 1298.

https://doi.org/10.1182/blood-2019-125931

Published: 2019

Journal Articles

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

Deok-Hwan Yang, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Young Rok Do, PhDMD, Sang Yun Song, MD PhD, Ga-Young Song, Hyeong Jong Kim, MD, Theresa Kim

Blood (2019) 134 (Supplement_1): 2329.

https://doi.org/10.1182/blood-2019-126533

Published: 2019

Journal Articles

Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma

Krystle Nomie, PhD, Nikita Kotlov, PhD, Viktor Svekolkin, PhD, Alexander Bagaev, PhD, Qingsong Cai, PhD, Jasmine Falahat, Omar Moghrabi, Felix Frenkel, PhD, Ravshan Attaulakhanov, PhD, Angela Leeming, Dayoung Jung, Holly Hill, Kelley Paige Murfin, MSPH, Zhihong Chen, Kimberly Hartig, Maria Badillo, Preetesh Jain, MBBS,MDDM,PhD, Liang Zhang, MD PhD, Michael Wang, MD

Blood (2019) 134 (Supplement_1): 2762.

https://doi.org/10.1182/blood-2019-130512

Published: 2019

Journal Articles

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

C. Chris Huang, PhD, Yumi Nakayama, PhD, Matthew Stokes, PhD, Fadi Towfic, PhD, chung-Wein Lee, Yan Ren, Mathieu Marella, PhD, Maria Wang, Patrick R. Hagner, PhD, Suzana Couto, Kathryn Newhall, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 2797.

https://doi.org/10.1182/blood-2019-123691

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD

Blood (2019) 134 (Supplement_1): 2807.

https://doi.org/10.1182/blood-2019-128036

Published: 2019

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Jing Fu, PhD, Shirong Li, PhD, Chen Yang, Lewis M Brown, PhD, Stephen J Weiss, MD PhD, Charles G Drake, MD PhD, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3072.

https://doi.org/10.1182/blood-2019-129177

Published: 2019

Journal Articles

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

Francesca Arruga, PhD, Giulia Guerra, Denis Baev, PhD, Catherine Hoofd, PhD, Marta Coscia, MD PhD, Giovanni Francesco D'Arena, MD, Gianluca Gaidano, MD PhD, Richard R. Furman, MD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 5454.

https://doi.org/10.1182/blood-2019-128308

Published: 2019

Journal Articles

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

Alexander Slota, MD, Roomana Khan, MD, Akhil Rahman, MD, Eiran A Warner, MD

Blood (2019) 134 (Supplement_1): 5630.

https://doi.org/10.1182/blood-2019-127586

Published: 2019

Journal Articles

ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis

Emel Unal, Derya Ozyoruk, Nurdan Tacyildiz, Ferda Pi̇narli̇, A Erdogan, S Hanalioglu, Arzu Erdem, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 5632.

https://doi.org/10.1182/blood-2019-130102

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Checkpoint inhibitors and thrombosis: what’s up?

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only